Dow Jones Newswires: J&J: Study shows ‘real world evidence' of COVID vaccine's protection against breakthrough infectionMarket Watch • 01/06/22
Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United StatesPRNewsWire • 01/06/22
Johnson & Johnson, Shaking Off Its Stodgy Image, Is One of Our Stock Picks for 2022Barrons • 01/01/22
Johnson & Johnson COVID booster offers serious protection against hospitalization from omicron variantCNET • 12/30/21
J&J's COVID-19 vaccine booster was 85% effective against hospitalization, in South Africa studyMarket Watch • 12/30/21
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was DominantPRNewsWire • 12/30/21
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 12/30/21
Invest Like Warren Buffett in 2022 and Buy These 3 Stocks for the Long HaulThe Motley Fool • 12/29/21